Lyell Immunopharma, Inc. - Common Stock (LYEL)

Lyell Immunopharma (NASDAQ:LYEL) expects pivotal data in mid-2027 for its lead CAR-T cell therapy, ronde-cel, as the company advances the treatment in patients with large B-cell lymphoma who have received at least two prior lines of therapy. President and CEO Dr. Lynn Seely said Lyell is completing

Lyell Immunopharma (NASDAQ:LYEL) President and CEO Lynn Seely outlined the company’s clinical development priorities, regulatory strategy and manufacturing plans during a Stifel investor session moderated by Stephen Willey, senior biotech analyst at Stifel. Seely described Lyell as a cell therapy c

Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Lyell Immunopharma reports Q2 2025 with a narrower loss than expected, driven by cost controls. Clinical progress for CAR T-cell therapy LYL314 remains strong, with pivotal trials advancing. Cash runway extends to mid-2027.

Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.

Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes.

Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top gainers and losers in today's session.

Lyell Immunopharma acquires ImmPACT Bio, ends TIL programs, and refocuses on CAR T-cell research. Analyst downgrades reflect concerns over pipeline complexities.

LYEL stock results show that Lyell Immunopharma beat analyst estimates for earnings per share the second quarter of 2024.

Investors should keep a watchful eye out for these three biotech stocks to sell before a potential dip damages their gains.

Lyell Immunopharma shares fell following the release of initial clinical data from its Phase 1 trial of LYL797, a reprogrammed CAR T-cell product. The company reported some severe cases reported in patients with lung metastases.